Immutep's IMP761 Shows Promising Early Data in Phase I Trial
Event summary
- Immutep's Phase I trial for IMP761 met primary safety and tolerability endpoints in healthy volunteers.
- Statistically significant pharmacodynamic activity observed at 7 mg/kg dose in a placebo-controlled setting.
- Data presented at EULAR 2026 Congress on June 4, 2026, supports further clinical investigation in autoimmune diseases.
- Additional trial updates expected in the second half of 2026.
The big picture
Immutep's positive Phase I data for IMP761 underscores the growing interest in LAG-3 biology for autoimmune therapies. The results position IMP761 as a potential first-in-class treatment, addressing significant unmet needs in conditions like rheumatoid arthritis. The biotech sector is closely watching the progression of LAG-3 agonists, which could redefine immune modulation strategies.
What we're watching
- Clinical Progression
- Whether IMP761 can maintain its efficacy and safety profile in Phase II trials targeting specific autoimmune diseases.
- Strategic Collaborations
- The likelihood of Immutep securing partnerships to accelerate IMP761's development and commercialization.
- Market Positioning
- How Immutep positions IMP761 against existing treatments for rheumatoid arthritis and other T-cell driven conditions.
Related topics